GlassScriptPhysician profile
John Michael Humeniuk
NPI 1639164528
$41,586.70
in general payments reported to CMS, 2019-2025
28 companies · $1,626 in 2025
The $1,626 reported for 2025 was more than what a typical Procedural Dermatology provider received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26K · 2020: $2,895 · 2021: $4,733 · 2022: $1,980 · 2023: $2,624 · 2024: $2,124 · 2025: $1,626.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,179 · Education: $196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,178.82 |
| Education | $196.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $23,397.71 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $6,043.52 | 2019-2024 | |
| Ucb, INC. | $3,206.57 | 2019-2023 | Cimzia |
| Janssen Biotech, INC. | $2,219.18 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Pfizer INC. | $1,586.62 | 2019-2025 | |
| Lilly USA, LLC | $1,089.59 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Genzyme Corporation | $800.56 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $778.95 | 2019-2025 | Ilumya |
| Amgen INC. | $498.30 | 2020-2025 | Otezla |
| E.R. Squibb & Sons, L.L.C. | $353.55 | 2022-2025 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $320.54 | 2019-2025 | Siliq, Targretin, Duobrii |
| Janssen Scientific Affairs, LLC | $316.73 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $291.21 | 2019-2024 | Libtayo |
| Leo Pharma INC. | $231.26 | 2022-2025 | Adbry |
| Celgene Corporation | $108.75 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $97.60 | 2023-2025 | Zoryve |
| Vyne Pharmaceuticals INC. | $90.83 | 2020-2021 | |
| Incyte Corporation | $30.91 | 2022-2023 | Opzelura |
| Dendreon Pharmaceuticals LLC | $27.38 | 2025 | Provenge |
| Organon LLC | $26.28 | 2023 | Hadlima |
| Paratek Pharmaceuticals, INC. | $21.44 | 2021 | |
| Mayne Pharma Commercial LLC | $19.01 | 2023 | |
| Qiagen, LLC | $17.04 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Humeniuk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.